_ 1	_
Please type a plus sign (+) inside this box ->	Y

PTO/SB/05 (4/98)

Please type a plus sign (+) inside this box
Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

Attomey Docket No.

First Inventor or Application Identifier Wang Chimeric Protein For the Diag,

(Only for new non	provisional applications under 37 C.F.R. § 1.53(b), Expre.	ss Mail Label No.
API See MPEP chapi	PLICATION ELEMENTS ter 600 concerning utility patent application contents.	Assistant Commissioner for Patents ADDRESS TO: Box Patent Application Washington, DC 20231
1. X Fee (Subtr. 2. X Spec (prefe - Des - Cro - Sta - Ref - Bac - Brie - Brie - Det - Cla - Abs 3. X Draw 4. Oath or De a	e Transmittal Form (e.g., PTO/SB/17) mit an original and a duplicate for fee processing) cification [Total Pages 44] cification [Total Pages 44] scriptive title of the Invention as References to Related Applications atement Regarding Fed sponsored R & D ference to Microfiche Appendix ckground of the Invention ef Summary of the Invention ef Description of the Drawings (if filed) tailed Description aim(s) stract of the Disclosure wing(s) (35 U.S.C. 113) [Total Sheets 9] Copy from a prior application (37 C.F.R. § 1.63(a) (for continuation/divisional with Box 16 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b). EMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY LENTITY STATEMENT IS REQUIRED 37 C.F.R. § 1.27, EXCEPT	5. Microfiche Computer Program (Appendix) 6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to computer copy) c. Statement verifying identity of above copps ACCOMPANYING APPLICATION PARTS 7. Assignment Papers (cover sheet & document(s)) 8. 37 C.F.R.§3.73(b) Statement Power of (when there is an assignee) 9. English Translation Document (if applicable) 10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations 11. Preliminary Amendment 12. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 13. Statement(s) Statement filed in prior application Status still proper and desired (PTO/SB/09-12) 14. (if foreign priority is claimed) 15. Other:
16. If a CON Con Prior apple	ntinuation Divisional Continuation-in-part (Continuation in-part (of the prior application, from which an oath or declaration is supplied ying continuation or divisional application and is hereby incorporated by has been inadvertently omitted from the submitted application parts.
reference. The	17. CORRESPONDE	NCE ADDRESS
Custome	er Number or Bar Code Label (Insert Customer No. or Att	or
Name	- Mark Farber Alexion Pharmecuticals,	Inc.
Address	25 Science Park, Suite 3 New Haven, CT. 06511	
City	State	Zip Code
Country	II S Telephone	Fax
Name (Pi	Mark Farber M. " L	Hegistration No. (Attorney/Agent) 34,159 Tur. Jun Date > /2-[(00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PCT

PTO/SB/17 (12/99)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTA Complete if Known **Application Number** PCT/US98/27408 for FY 2000 Filing Date 23 December 1998 Patent fees are subject to annual revision. First Named Inventor Yi Wang Small Entity payments must be supported by a small entity statement, Examiner Name otherwise large entity fees must be paid. See Forms PTO/SB/09-12. See 37 C.F.R. §§ 1.27 and 1.28. Group / Art Unit

Attorney Docket No.

METHOD OF PAYMENT (check one)	FEE CALCULATION (continued)			
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to: Description:	3. ADDITIONAL FEES Large Entity Small Entity Fee Fee Fee Fee Fee Fee Pee Fee Fee Fee			
Account Number 01-0483	Code (\$) Code (\$) 105 130 205 65 Surcharge - late filing fee or oath			
Deposit	127 50 227 25 Surcharge - late provisional filing fee or cover sheet.			
Name Alexion Pharmaceutical	Inc. 139 130 139 130 Non-English specification			
Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17	147 2,520 147 2,520 For filing a request for reexamination			
A	112 920* 112 920* Requesting publication of SIR prior to Examiner action			
2. Payment Enclosed: Money Other Other	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action			
FEE CALCULATION	115 110 215 55 Extension for reply within first month			
	116 380 216 190 Extension for reply within second month	,		
1. BASIC FILING FEE	117 870 217 435 Extension for reply within third month			
Large Entity Small Entity Fee Fee Fee Fee Description	118 1,360 218 680 Extension for reply within fourth month	<u> </u>		
Code (\$) Code (\$) Fee Paid	128 1,850 228 925 Extension for reply within fifth month			
101 690 201 345 Utility filing fee	0119 300 219 150 Notice of Appeal			
106 310 206 155 Design filing fee	120 300 220 150 Filing a brief in support of an appeal			
107 480 207 240 Plant filing fee	121 260 221 130 Request for oral hearing			
108 690 208 345 Reissue filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding			
114 150 214 75 Provisional filing fee	140 110 240 55 Petition to revive - unavoidable			
SUBTOTAL (1) (\$) 345.00	141 1,210 241 605 Petition to revive - unintentional	\$ 605.00		
2. EXTRA CLAIM FEES	142 1,210 242 605 Utility issue fee (or reissue)			
Fee from Extra Claims below Fee Paid	143 430 243 215 Design issue fee			
Total Claims 1 9 -20** = 0 X 18 = 0	144 580 244 290 Plant issue fee			
Independent 9 - 3** = 6 x 39 = \$234	0022 130 122 130 Petitions to the Commissioner			
Multiple Dependent =	123 50 123 50 Petitions related to provisional applications			
**or number previously paid, if greater; For Reissues, see below	126 240 126 240 Submission of Information Disclosure Stmt			
Large Entity Small Entity Fee Fee Fee Fee Fee Description	581 40 581 40 Recording each patent assignment per property (times number of properties)			
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	146 690 246 345 Filing a submission after final rejection			
102 78 202 39 Independent claims in excess of 3	(37 CFR § 1.129(a)) 149 690 249 345 For each additional invention to be			
104 260 204 130 Multiple dependent claim, if not paid	149 690 249 345 For each additional invention to be examined (37 CFR § 1.129(b))			
109 78 209 39 ** Reissue independent claims over original patent	Other fee (specify)			
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	Other fee (specify)			
SUBTOTAL (2) (\$) 234_00	Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 605.00			
SUBMITTED BY	Complete (if applicable)			
Name (Print/Type) Mark Farber	Registration No. (Altorney/Agent) 34,159 Telephone (203) 7	776-1790		
Signature Mark For		00		

WARNING:

TOTAL AMOUNT OF PAYMENT (\$)

Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



Docket:

21

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Wang et al.

Filed:

December 23, 1998

Group:

Unassigned

Serial No:

PCT/US98/27408

Examiner:

Unassigned

For:

Chimeric Proteins For Diagnosis And Treatment Of Diabetes

APPLICATION TRANSMITTAL LETTER

Asst. Commissioner For Patents Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the [x] utility $[\]$ design patent

appli	icatio	on in this case including:
1.	ſĵ	This application is a [] Continuation; [] Divisional Continuation in Part of prior application Serial filed on [entire genealogy should be set forth].
2.	[]	This application claims priority from Provisional Application No, filed
3.	[]	The application consisting of $\underline{44}$ pages (including specification, claims and abstract).
4.	[]	9 sheet(s) of drawings is enclosed. The drawings are:
	a. b.	<pre>[] formal; or [x] informal; formal drawings will be submitted in due course</pre>
5.	[]	A signed declaration and power of attorney is enclosed.
6.	[x]	A declaration and power of attorney is <u>not</u> enclosed at this time since it <u>has not</u> been executed by the inventor(s). A signed declaration and power of attorney will be submitted in due course.
	The	inventor(s) is/are

- 7. [] An Assignment of the invention to ______ is enclosed. Please record the Assignment and return it to the undersigned. TWO DUPLICATE COPIES OF THIS PAPER ARE ENCLOSED.
- 8. [] The Application filing fee is calculated below.

No. F	led		No. Extra*	Rate:	<u> Fee</u>
Basic Fee: Total Claims: Indep Claims:	18 - 20 9 - 3	= =	0 6	x 9.00 x 39.00	\$ 345.00 \$ 0.00 \$ 234.00
[] Multiple Presented	Dependent Clai	+ \$270.00		\$0.00	

TOTAL: \$ 579.00

- 9. [] Please charge Deposit Account No. 01-0483 in the amount of \$\,\text{\text{which includes filing fee and recordation fee}}\). **TWO DUPLICATE COPIES OF THIS PAPER ARE ENCLOSED.**
- 10. [x] The Commissioner is hereby authorized to charge any additional fees which may be required for this application, or credit any overpayment to Deposit Account No. 01-0483. TWO DUPLICATE COPIES OF THIS SHEET ARE ENCLOSED.

Respectfully submitted,

Date: 3/21/00

Mark Farber

Reg. No. 34,159

Attorney for Applicant

Mark Farber C/O Alexion Pharmaceuticals, Inc. 25 Science Park, Suite 360 New Haven, CT. 06511



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Wang et al.

Serial No:

PCT/US98/27408

Examiner:

Unassigned

Filed:

December 23, 1998

Group:

Unassigned

For:

Chimeric Proteins For Diagnosis and Treatment of Diabetes

38 CFR §1.137 (b) PETITION FOR REVIVAL OF UNINTENTIONALLY ABANDONED APPLICATION

Asst. Commissioner For Patents Washington, DC 20231

Sir:

An Office Action was mailed by the United States Patent and Trademark Office on January 5, 1999. No response has been filed to date. Therefore, the application has become abandoned (although no Notice of Abandonment has been received from the USPTO). Such abandonment was unintentional.

Applicants respectfully petition for revival of the above identified application under the provisions of 37 CFR §1.137 (b). This petition is made within one year from the date of abandonment.

Enclosed is a check for the petition fee of \$ 605.00 as required under 37 CFR § 1.17 (m).

As a proposed response enclosed please find a Transmittal Letter and fee for a filing a patent application under 35 USC § 371.

All the requirements of 37 CFR §1.137 (b) having been complied with, it is courteously requested that this application be restored to pending status.

The Commissioner is hereby authorized to charge any additional fees which may be required for this application, or credit any overpayment to Deposit Account No. TWO DUPLICATE COPIES OF THIS SHEET ARE ENCLOSED.

Dato: 3/21/00

Respectfully Submitted,

Mark Farber Reg. No. 34,159

Attorney for Applicant

Mark Farber C/O Alexion Pharmaceuticals, Inc. 25 Science Park, Suite 360 New Haven, CT 06511

A

Docket No. 21 PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Wang et al.

Serial No:

PCT/US98/27408

Examiner:

Unassigned

Filed:

December 23, 1998

Group:

Unassigned

For:

Chimeric Proteins For Diagnosis and Treatment of Diabetes

Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF EXPRESS MAILING

Date of Deposit: <u>March 21 , 2000</u> EXPRESS MAILING NUMBER: <u>EJ513609638US</u>

I hereby certify that the following:

- [x] This Certificate of Mailing
- [x] Petition to Revive
- [x] Fee Transmittal for FY 2000
- [x] Utility Patent Application Transmittal
- [x] Application Transmittal Letter
- [x] Check
- [x] Return postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Carolynn Wise

Alexion Pharmaceuticals, Inc. 25 Science Park, Suite 360 New Haven, CT. 06511